Decibel Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

decibeltx.com

Founded Year

2015

Stage

IPO | IPO

Total Raised

$189M

Date of IPO

2/12/2021

Market Cap

0.06B

Stock Price

3.60

About Decibel Therapeutics

Decibel Therapeutics (NASDAQ: DBTX) is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing. By combining recent innovations in hearing science with diagnostic tools, biological insights, modeling, and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough drugs targeted to specific indications and patients.

Decibel Therapeutics Headquarter Location

1325 Boylston Street Suite 500

Boston, Massachusetts, 02215,

United States

617-370-8701

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Decibel Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Decibel Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Decibel Therapeutics Patents

Decibel Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Audiology
  • Alkylating antineoplastic agents
  • Antineoplastic drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/13/2020

7/27/2021

Food additives, Antineoplastic drugs, Alkylating antineoplastic agents, Polysaccharides, Excipients

Grant

Application Date

7/13/2020

Grant Date

7/27/2021

Title

Related Topics

Food additives, Antineoplastic drugs, Alkylating antineoplastic agents, Polysaccharides, Excipients

Status

Grant

Latest Decibel Therapeutics News

Decibel Therapeutics (DBTX) Stock: Why It Surged 18.3%

Jun 29, 2022

The stock price of Decibel Therapeutics Inc (NASDAQ: DBTX) surged by 18.3% in the most recent trading session. This is why. The stock price of Decibel Therapeutics Inc (NASDAQ: DBTX) – a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance – surged by 18.3% in the most recent trading session. Investors are responding positively to Decibel Therapeutics reporting positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a novel, proprietary formulation of sodium thiosulfate (STS) designed to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. Cisplatin – one of the most commonly used chemotherapeutic agents – has severe dose-limiting side effects, including ototoxicity, which leads to permanent hearing loss in many patients. There are no approved therapies to prevent or treat cisplatin-induced ototoxicity. The patients enrolled in the Phase 1b clinical trial were randomized to receive one of two doses of DB-020 in one ear while the contralateral ear received placebo, enabling each patient to serve as their own control. Patients were administered DB-020 and placebo up to three hours prior to each cisplatin infusion. Consistent with the results of a Phase 1 clinical trial of DB-020 previously completed by the Company in healthy volunteers, data from the interim analysis demonstrated that DB-020 was well tolerated, with adverse events generally mild to moderate. In the data from the interim analysis, 88% of patients experienced ototoxicity in their placebo-treated ear, and of these patients, 87% were partially or completely protected from ototoxicity in their DB-020-treated ears. The interim analysis includes data collected as of February 4, 2022, from 19 cisplatin-naïve cancer patients being treated with high doses of cisplatin every 21 or 28 days. And of the 19 patients in the interim analysis, 17 patients had evaluable audiograms at baseline and after being dosed with DB-020 in one ear and placebo in the contralateral ear in conjunction with their prescribed infusion of cisplatin chemotherapy. Ototoxicity was defined according to the American Speech-Language-Hearing-Association (ASHA) criteria for significant ototoxic change. Key findings: 2.) DB-020, administered prior to cisplatin, had no apparent effect on systemic cisplatin levels. 3.) 13 of 17 (76.5%) patients experienced cisplatin-induced ototoxicity in the placebo ear after the first cycle of cisplatin; 15 of 17 (88.2%) patients experienced cisplatin-induced ototoxicity in the placebo ear by the last evaluable test. a.) Placebo-treated ears lost approximately 30dB on average from baseline in high frequencies, shifting patients from normal or slight hearing loss to moderate hearing loss (two hearing loss categories) on average. 4.) In the 15 patients who experienced ototoxicity in the placebo ear by the last evaluable test, DB-020 protected 13 (87%) from ototoxicity in their DB-020-treated ear. a.) 8 of 15 (53.3%) were completely protected, and 5 of 15 (33.3%) were partially protected. (Complete protection was defined as no change in hearing from baseline in the ear that received DB-020 according to the ASHA ototoxicity criteria in the clinically assessed range.) b.) Ears treated with DB-020 lost approximately 8dB on average from baseline. 5.) DB-020 reduced cisplatin-induced loss of speech audibility by 80% as measured by the Speech Intelligibility Index, suggesting treatment with DB-020 may reduce the risk of needing assistive hearing devices after receiving cisplatin. KEY QUOTE: “These data support the approach and rationale for DB-020 and represent an important step forward in the development of DB-020 for patients receiving cisplatin chemotherapy. We are tremendously encouraged by the favorable safety profile and protection against ototoxicity we have observed in the trial as of the interim analysis. These promising data support continued development of DB-020 to prevent or minimize cisplatin-induced hearing loss, an irreversible condition for which there are currently no available treatments.” — John Lee, Chief Development Officer of Decibel “Cisplatin remains an important chemotherapy for the treatment of multiple cancer types, both as a single agent and in combination therapy, and is used routinely in my patients. Administration of DB-020 was generally well tolerated, and did not appear to alter systemic cisplatin levels, reducing concern of impacting the chemotherapeutic benefits of cisplatin on cancer management.” — Dr. Danny Rischin, Director of the Division of Cancer Medicine and Head of the Department of Medical Oncology at Peter MacCallum Cancer Centre, Melbourne, Australia “Decibel’s trial underscores the magnitude of hearing loss experienced by cisplatin-naïve cancer patients receiving cisplatin chemotherapy even after a single cycle of cisplatin. Decibel’s interim analysis provides evidence that DB-020 has exciting potential to prevent cisplatin-induced hearing loss and we look forward to continuing to evaluate the effectiveness of DB-020.” — Dr. Ben Panizza, Director of the Queensland Head and Neck Cancer Centre, Brisbane, Australia “We believe these positive data showcase the integrated capabilities that Decibel has implemented to develop innovative therapeutics for conditions of the inner ear. We look forward to reporting additional data from the interim analysis of our ongoing clinical trial of DB-020 at an upcoming medical conference, as we continue to advance our broader pipeline, focused on creating a world of connection for people with hearing and balance disorders.” — Laurence Reid, Ph.D., Chief Executive Officer of Decibel Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Decibel Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Decibel Therapeutics Rank

  • When was Decibel Therapeutics founded?

    Decibel Therapeutics was founded in 2015.

  • Where is Decibel Therapeutics's headquarters?

    Decibel Therapeutics's headquarters is located at 1325 Boylston Street, Boston.

  • What is Decibel Therapeutics's latest funding round?

    Decibel Therapeutics's latest funding round is IPO.

  • How much did Decibel Therapeutics raise?

    Decibel Therapeutics raised a total of $189M.

  • Who are the investors of Decibel Therapeutics?

    Investors of Decibel Therapeutics include Google Ventures, Third Rock Ventures, SR One, S-Cubed Capital, Foresite Capital and 14 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.